Reply: 18F-FDG PET for Routine Posttreatment Surveillance in Oral and Oropharyngeal Squamous Cell Carcinoma

2010

1164 Objectives 68Ga-BPAMD (BPAMD = (4-{[bis-(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxy methyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid) was used in a first human in vivo study for diagnosis of osteoblastic bone metastases. The DOTA-based bisphosphonate ligand BPAMD may also be suitable for complexation with therapeutic radionuclides such as 177Lu. The same ligand thus may be used for diagnosis, dosimetry calculation, therapy and therapy control via PET/CT. Methods 177Lu was provided in 0.04 M HCl via the 176Yb(n,γ)177Yb→177Lu production process. Labelling was studied using different amounts of ligand in acetate buffer at pH 4-5 and different temperatures. For quality control…